Ubrogepant & Migraines

Ubrogepant (brand name Ubrelvy) belongs to a class of medications called gepants, or small-molecule CGRP receptor antagonists. CGRP (calcitonin gene-related peptide) is a protein that plays a central role in migraine attacks by promoting inflammation and pain signaling in the trigeminal nerve system. Ubrogepant blocks the CGRP receptor, preventing this protein from triggering its cascade of effects.

Approved by the FDA in 2019, ubrogepant represents a fundamentally different approach from triptans. While triptans constrict blood vessels, ubrogepant does not. This makes it a potential option for people who cannot use triptans due to cardiovascular concerns or who haven't responded well to triptans.

Ubrogepant is available in 50 mg and 100 mg tablets. The recommended dose is 50 mg or 100 mg taken at the onset of migraine headache. If the first dose provides partial relief or the migraine returns, a second dose can be taken at least two hours later. The maximum dose in 24 hours is 200 mg.

Unlike triptans, which are taken during the pain phase only, some research suggests ubrogepant may also be effective when taken during the prodrome phase (the early warning stage before headache begins). This is being studied further. Ubrogepant can be taken with or without food, and it doesn't need to be taken with water if the orally disintegrating form becomes available in your market.

Ubrogepant's side effect profile is relatively mild. The most commonly reported effects include nausea, somnolence (sleepiness), and dry mouth, but these occur at rates only slightly above placebo. Notably absent are the triptan-like chest tightness and tingling sensations that bother some people.

Because ubrogepant doesn't constrict blood vessels, it doesn't carry the cardiovascular warnings that come with triptans. This is a significant advantage for people with heart disease risk factors. An important drug interaction to know about: ubrogepant is broken down by the CYP3A4 enzyme, so strong inhibitors of this enzyme (like ketoconazole or clarithromycin) can increase its levels. Grapefruit juice can also affect metabolism.

Two large Phase 3 clinical trials (ACHIEVE I and ACHIEVE II) demonstrated ubrogepant's effectiveness. The 100 mg dose provided pain freedom at two hours in about 21% of participants (vs. 12% placebo) and pain relief in about 61% (vs. 49% placebo). While these numbers may seem modest, they represent statistically significant improvement.

An interesting finding from longer-term studies is that ubrogepant's effectiveness may actually improve with repeated use, unlike triptans where some people report decreasing benefit over time. Studies also suggest a lower risk of medication overuse headache compared to triptans and NSAIDs, though more research is needed to confirm this potential advantage.

Because ubrogepant is relatively new, your personal tracking data is especially valuable. You're essentially building your own evidence base for how this medication works for your specific migraine pattern. Log each use in CalmGrid along with timing, symptoms, and pain levels before and after.

Comparing ubrogepant entries with your previous triptan or NSAID entries gives you concrete data about whether this newer option performs better for you. Track not just pain relief but also side effects, speed of onset, and whether migraines return after initial improvement. This comprehensive record helps your neurologist make informed decisions about continuing, adjusting, or combining ubrogepant with other treatments.